anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The main objective was to evaluate structural and functional connectivity correlates of fatigue in post-COVID syndrome, and to investigate the relationships with an objective measure of mental fatigue and with subjective cognitive complaints. One-hundred and twenty-nine patients were recruited after 14.79 ± 7.17 months. Patients were evaluated with fatigue, neuropsychological, and subjective cognitive complaints assessments. Structural and functional magnetic resonance imaging were acquired, and functional connectivity, white matter diffusivity and grey matter volume were evaluated. Fatigue was present in 86 % of patients, and was highly correlated to subjective cognitive complaints. Fatigue was associated with structural and functional connectivity mostly in frontal areas but also temporal, and cerebellar areas, showing mental fatigue different pattern of functional connectivity correlates compared to physical fatigue. White matter diffusivity correlates were similar in fatigue and subjective cognitive complaints, located in the forceps minor, anterior corona radiata and anterior cingulum. Findings confirm that fatigue in post-COVID syndrome is related to cerebral connectivity patterns, evidencing its brain substrates. Moreover, results highlight the relationship between fatigue and subjective cognitive complaints. These findings point out the relevance of the multidisciplinary assessment of post-COVID syndrome patients with subjective cognitive complaints, in order to unravel the symptomatology beneath the patient's complaints.
COVID-19 and infectious diseases have been included in strategic development goals (SDG) of United Nations (UN). The SARS-CoV-2 pandemic has unveiled complex pathophysiological mechanisms underpinning COVID-19, notably inducing a systemic acquired vascular hemopathy characterized by endothelial dysfunction and intussusceptive angiogenesis, a rapid vascular remodeling process identified as a hallmark in severe COVID-19 cases affecting pulmonary and cardiac tissues. Stem cell migration have been proposed as significant regulators of this neoangiogenic process. In a monocentric cross-sectional study, through spectral flow cytometry analysis of peripheral blood mononuclear cells, we identified a distinct stem cell subpopulation mobilized in critical COVID-19. Indeed, by an unsupervised analysis generating a UMAP representation we highlighted eleven different clusters in critical and non-critical COVID-19 patients. Only one cluster was significantly associated to critical COVID-19 compared to non-critical patients. This cluster expressed the markers: CD45dim, CD34+, CD117+, CD147+, and CD143+, and were negative for CD133. Higher level of expression of hemangioblast markers CD143 were found in critical COVID-19 patients. This population, indicative of hemangioblast-like cells, suggests a key role in COVID-19-related neoangiogenesis, potentially driving the severe vascular complications observed. Our findings underscore the need for further investigation into the contributions of adult stem cells in COVID-19 pathology, offering new insights into therapeutic targets and interventions.
Inhibitor of β-catenin and T-cell factor (ICAT) is a classical inhibitor of the Wnt signaling pathway. Nonetheless, our previous work found that ICAT is overexpressed in cervical cancer (CC), resulting in the augmentation of migration and invasion capabilities of CC cells. It remains unclear what molecular mechanism underlies this phenomenon. The interaction between cancer cells and the tumor microenvironment (TME) promotes the outgrowth and metastasis of tumors. Tumor-associated macrophages (TAMs) are a major constituent of the TME and have a significant impact on the advancement of CC. Consequently, our inquiry pertains to the potential of ICAT to facilitate tumor development through its modulation of the cervical TME. In this study, we first verified that ICAT regulated the secretion of cytokines interleukin-10 (IL-10) and transforming growth factor-β (TGF-β) in CC cells, leading to M2-like macrophage polarization and enhancement of the migration and invasion of CC cells. Furthermore, the system of co-culturing human umbilical vein endothelial cells (HUVECs) with macrophages revealed that depending on the CC cells' overexpression or inhibition of ICAT, the vascular tube formation by HUVECs can be either increased or decreased. Overall, our study indicates that ICAT stimulates M2-like polarization of TAMs via upregulating IL-10 and TGF-β, which results in increased neovascularization, tumor metastasis, and immunosuppression in CC. In upcoming times, inhibiting crosstalk between CC cells and TAMs may be a possible strategy for CC therapy.
Concomitant medications that can induce or inhibit CYP3A4 or N-acetyl-transferases may affect the pharmacokinetics of zonisamide. Drugs which inhibit or induce glucuronide conjugation are not expected to influence the pharmacokinetics of zonisamide.

The absence of a clinically significant pharmacokinetic interaction between zonisamide and lamotrigine indicates a low potential for zonisamide to interact with substances which are metabolized by UDP-GT.

CYP3A4 Induction: Drugs that induce liver enzymes increase the metabolism and clearance of zonisamide and decrease its half-life. The half-life of zonisamide following a 400 mg dose in patients concurrently on enzyme-inducing AEDs such as phenytoin, carbamazepine, or phenobarbital was between 27 to 38 hours, the half-life of zonisamide in patients concurrently on the non-enzyme inducing AED, valproate, was 46 hours. 

These effects are unlikely to be of clinical significance when Zonisamide is added to existing therapy; however, changes in zonisamide concentrations may occur if concomitant CYP3A4 inducing anti-epileptic or other drugs are withdrawn, dose adjusted or introduced, an adjustment of the Zonisamide dose may be required. If co-administration with a potent CYP3A4 inducer (e.g., rifampicin) is necessary, the patient should be closely monitored and the dose of Zonisamide and other drugs that are CYP3A4 substrate may need to be adjusted.

CYP3A4 Inhibition: Steady-state dosing of either ketoconazole (400 mg/day) or cimetidine (1200 mg/day) had no clinically relevant effects on the single dose pharmacokinetics of zonisamide given to healthy subjects. Therefore, modification of Zonisamide dosing is not necessary when co-administered with known CYP3A4 inhibitors.
Perforation is the rarest complication of duodenal diverticulum but also one of its most serious complications. Mortality rate was reported to up to 30%. Clinical diagnosis is usually vague and non-specific. High clinical suspicion is important as rapid deterioration is likely. Consensus regarding management is lacking and currently guided by a small series of case reviews. Surgical treatment is historically the standard therapeutic option. However, more current literature suggests improvement in patients with non-surgical management. In this paper, we discuss a case of a patient in her early 60s who had a perforated duodenal diverticulum that was treated conservatively. It highlights the importance of a good history and a CT scan to help with diagnosis. Close clinical observation is essential to detect disease progression. A step-up approach to clinical deterioration with either percutaneous drainage or surgical management should be considered if the patient does not respond to conservative treatment.
The present invention provides a peroxisome proliferator-activated receptor (PPAR) activator which is free from the problem of side effects, can be taken over a long period of time and has no characteristic flavor, and provides drugs, supplements, functional foods and food additives using the activator. Nobiletin is used as a PPAR activator. Nobiletin, which has an excellent PPAR activity and an excellent effect of promoting adiponectin secretion, is contained in a large amount in citrus fruits, in particular, Citrus depressa HAYATA indigenous to Okinawa. Because of having been taken over many years, citrus fruits are free from any problem in safety and have low caloric values. Thus, they can be taken over a long period of time. Nobiletin is tasteless and odorless and therefore it can be added to a food without damaging the characteristic taste of the food. Owing to these characteristics, nobiletin can be added to foods and taken.
Participants will receive an individualized home exercise program on paper and one instructional session. They will receive written instructions on performing the program 2-3 times weekly and instructions on exercise progression. They will receive no support during the 10-week period.
PURPOSE:To obtain an antitumor agent having stability to temperature, enzyme, etc., and effectively raised activity by using both a component separated from precipitate prepared by adding an organic solvent to a culture solution of bacteria belonging to the genus Streptococcus or an ultrafiltration filtrate thereof and picibanil. CONSTITUTION:Streptococcus pyogenes ATCC 21,060 belonging to the genus Streptococcus are cultured in a medium and cells are removed by centrifuging to collect a culture solution. The culture solution or a concentrated ultrafiltration filtrate prepared by ultrafiltering and concentrating the culture solution is mixed with an organic solvent (e.g. methanol), allowed to stand, formed precipitate is separated, treated by a hydroxyapatite column, eluted with 0.01 M phosphoric acid buffer solution to give SpF-pCO-20 or with 0. 25 M phosphoric acid buffer solution to give SpF-PCO-30, respectively. A solution of the component is blended with picibanil to give the objective antitumor agent having effectively raised activity.
PURPOSE:To provide a method for processing propolis, carried out by treating propolis with a supercritical gas or a liquefied fluid so as to remove organic components composed mainly of waxes and capable of improving the grindability, of controlling strong smell components in extraction and of preventing generation of dregs. CONSTITUTION:A raw material propolis (kind of bee resin), i.e., a glue-like substance accumulated in a honeycomb is cut into pieces of 5mm square by a cutter, filled into an autoclave and treated by using a supercritical fluid treatment apparatus and a supercritical gas composed of carbon dioxide under conditions of 5ml/min flow rate, 40 deg.C and 250atm for 6hr. A liquefied fluid may be used for the treatment. Thereby, organic components composed mainly of fragrant components, flavonoid compounds and waxes contained in the propolis are extracted and concentrated and grindability of the propolis is improved. In addition, strong smell components can be controlled in extraction of propolis and generation of dregs can be prevented. According to the above-mentioned method, the objective propolis widely useful for a health food, propolis tincture, a candy or another food, etc., can be produced.
Participants in this group will take part in 7 dog-assisted therapy sessions (1 per week). This therapy will be added to their usual daily living and therapies. Assessments will be conducted before and after the 7-week program.
In order to predict which intensive care unit (ICU) patients are not likely to achieve target attainment of beta-lactam antibiotics, a diagnostic multivariable prediction model was developed using random forest analysis. Gender, age, creatinine, and type of beta-lactam antibiotic were included in the final model and translated into a user-friendly and easy-to-implement risk score. As the name suggests, the beta-lactam target non-attainment (BATMAN) risk score predicts which adult ICU patients fail to achieve target attainment and intents efficient use of TDM of beta-lactam antibiotics. In order to use the BATMAN risk score in as many hospitals as possible in clinical practice, an external validation will be performed by a multicenter prospective observational study. All adult ICU patients admitted to the participating hospitals that are treated with beta-lactam antibiotics will be screened for eligibility. One beta-lactam trough plasma concentration, clinical and non-clinical data will be collected prospectively. To our knowledge, no other beta-lactam target non-attainment risk score for adult ICU patients has yet been developed let alone externally validated. This research is essential because ICU patients are a highly heterogenic group of patients that undergo extensive physiological alterations that will have impact on antibiotic pharmacokinetics, such as beta-lactam antibiotics. For the beta-lactams, achievement of an adequate drug level is associated with a higher likelihood of clinical success and a decrease in the potential for antimicrobial resistance. Yet, target attainment remains a challenge with the traditional 'one-dose-fits-all' strategy.
OBJECTIVES: Haemophilia B (HB), characterised by deficient factor IX (FIX), leads to spontaneous bleeds. Severe cases require prophylactic FIX replacement. This post hoc analysis assessed the first spontaneous bleeds among previously untreated patients (PUPs) with HB treated with recombinant FIX Fc fusion protein (rFIXFc) (NCT02234310) to identify factors influencing bleeds.
METHODS: Subjects included paediatric PUPs with HB (≤2 IU/dL endogenous FIX). Analyses described treatment patterns (on demand [OD] vs. prophylaxis) and prophylaxis type (started on vs. switched to prophylaxis). Kaplan-Meier analyses assessed the time to first spontaneous bleed, including median time to event and fitting models with predictors for treatment regimen and/or baseline age.
RESULTS: PUPs B-LONG enrolled 33 subjects. Baseline age did not influence the time to first spontaneous bleed for any rFIXFc regimen. Those who started on prophylaxis with rFIXFc (n = 11), compared with those treated OD (n = 22), had an extended time to first spontaneous bleed. Starting prophylaxis afforded a 93% reduced risk of first spontaneous bleed versus starting OD (hazard ratio [95% confidence interval]: 0.071 [0.009-0.592]) (p = .015).
CONCLUSION: rFIXFc prophylaxis, particularly starting early, reduced the risk of bleeding and delayed time to first spontaneous bleed compared with rFIXFc OD. Hence, initial treatment regimens impact bleed patterns in paediatric PUPs.
Pec I block will be given with 10 ml bupivacaine 0.25% which injected between two pectoral muscles and pecs II block will be given with 20 ml bupivacaine 0.25%.which given between pectoralis minor muscle and serratus muscle. Patients will receive direct pecs block by surgeon after closure of pectoralis muscle under direct vision and before skin closure.
Participants enrolled in cohorts 5, 6, 7 or any other optional cohorts of Part 1 will roll-over in Part 2B and will receive a single oral dose (the same dose as received in Part 1) of JNJ-64417184 or placebo under fasted state. Dosing may be changed from fasted to a fed state, depending on emerging pharmacokinetics (PK) data from Part 2A.
Several scoring systems are used to evaluate the prognosis of acute pancreatitis, but they are rather complicated and clinically less useful. Blood viscosity is associated with hematocrit and inflammatory factors known to be related to the prognosis of acute pancreatitis, and our group's previous study which is not yet published showed that blood viscosity better predicts severe acute pancreatitis than other single factors such as C-reative protein. Therefore, this study aims to prospectively evaluate the usefulness of blood viscosity as a prognostic factor for acute pancreatitis. During the study period, the study is conducted on patients with acute pancreatitis between the ages of 19 and 70, and patients with acute pancreatitis after ERCP are excluded. Blood viscosities at initial and 24 hours after hospitalization, and serum phosphate, which have shown potential as a predictor of severity in post-ERCP pancreatitis in previous studies are measured. The association of these blood biomarkers with the severity of acute pancreatitis will be analyzed and compared with hematocrit, C-reactive protein, etc., which are known as a single prognostic predictor of acute pancreatitis.
Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
NEW MATERIAL:An ester of (i) a polyether polyol obtained by addition of an alkylene oxide to a tri- or more functional polyol (ii) a fatty acid selected from saturated straight chain/branched fatty acids, hydroxy fatty acids, unsaturated fatty acids and resin acids, and (iii) a dicarboxylic acid selected from aliphatic saturated/ unsaturated dicarboxylic acids and aliphatic oxydicarboxylic acids. EXAMPLE:Esterified products of glycerin, behenic acid and sebacic acid. USE:Oleagenous component for cosmetics and external preparations. It has excellent hydrophilic nature, compatibility with other oils, and gelling power. Highly stable to the skin. PROCESS:The above-mentioned polyether polyol (i), aliphatic acid (ii) and dicarboxylic acid (iii) are simultaneously or subsequently reacted by conventional process to give their ester.
PURPOSE:A bronchodilator containing nitric ester of N-(2-hydroxyethyl)nicotinic acid amide as an active constituent. CONSTITUTION:A bronchodilator containing nitric ester of N-(2-hydroxyethyl) nicotinic acid or a salt thereof found to be useful as a remedy for not only angina pectoris but also an asthmatic symptom. The bronchodilator is formulated into dosage forms of a tablet, capsule, granule, injection, inhalant or troche and administered in a dose of 5-200mg per day for an adult. The compound has very low toxicity and exhibits improved activity, and 25% remarkable effect is recognized by the administration of the compound at one time. The improvement of the asthmatic symptom is found in about 60% patients as a whole. 5mg compound is fully mixed with lactose, mannitol, and magnesium stearate, and the resultant mixture is used as a sublingual tablet.
Meperidine hydrochloride tablets are opioid agonists. Meperidine hydrochloride tablets are available as 50 mg for oral administration. The chemical name is 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-,ethyl ester, hydrochloride. The molecular weight is 283.80. Its molecular formula is C15H21NO2∙HCl, and it has the following chemical structure.

Meperidine hydrochloride is a white crystalline substance with a melting point of 186°C to 189°C. It is readily soluble in water and has a neutral reaction and a slightly bitter taste. The solution is not decomposed by a short period of boiling.

The tablets contain 50 mg of meperidine hydrochloride.

The Inactive Ingredients in meperidine hydrochloride tablets include: hypromellose, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, and stearic acid. Meperidine hydrochloride tablets 50 mg, are white, round, scored, and convex debossed with "214" on one side and "G" bisect "L"on the other side.
Individuals will perform Tai Chi exercises for 60 minutes, 3 days a week for 12 weeks. It includes 45 minutes of Tai Chi movements, 10 minutes of warm-up and 5 minutes of cool-down exercises. In addition, Diet will be recommended by the doctor as routine treatment.
The invention belongs to the technical field of microbial immunity, and particularly relates to dominant epitope peptides of a group of hantaan virus envelope glycoproteins, and coding genes and application thereof. The epitope peptide consists of a sequence shown in SEQ ID NO. 1-11. The invention obtains and verifies 11 candidate epitopes by screening and verifying an antigen specificity optimization epitope prediction and identification method for HTNV GP, and then verifies by simulating molecular docking. The immunoreactivity of the epitope in different isolates around the world is subjected to deep comparative analysis so as to verify the stability of the epitope in the vaccine application. In conclusion, the invention comprehensively evaluates the pan MHC-I immunoreactivity of HTNV GP according to comparative immunology, which is helpful for understanding the immunobiology of the HTNV GP and provides guidance for developing future HTNV epitope vaccines.
Systems and methods are disclosed for scheduling appointments based on changing health conditions of users. The method includes inputting the initial health dataset of a user to a machine learning model configured to identify other users with similar health profiles. A frequency of monitoring, a frequency of appointments, a duration between the appointments, or a type and length of the appointments is determined to generate a schedule of appointments. A subsequent health dataset of the user is received, and health scores, rule scores, or medication scores for the user are determined based on the subsequent health dataset. A plurality of risk scores for the user is evaluated based on the health scores, rule scores, or medication scores. A recent risk score is determined based on a change in the plurality of risk scores. The schedule of appointments is adjusted based on the recent risk score and the user is notified.
This is a single-center observational feasibility study to evaluate the overall performance of the surgical navigation system during robotic surgery, without impact on the surgical procedure itself. The duration of this study will be approximately 2.5 years. Patients scheduled for a sentinel node procedure at the NKI are eligible for inclusion. Patients are informed about the study before the planned surgery and, after being provided with the necessary information regarding participation in the study, will be asked for informed consent. No additional risk is expected using the NDI navigation setup. Patients will receive some additional radiation due to the CT scan during surgery; a perioperative CBCT scan (\~ 4 mSv) is acquired. This extra dose is low, considering other standard imaging in these patients like, pre-operative imaging with SPECT/CT scans. After surgery, no further participation or cooperation of the patient is required.
Cartilage preparations for use in healing wounds are obtained by subjecting cartilage to a proteolytic treatment and grinding the cartilage, before or after the proteolytic treatment, in the substantial absence of oxygen or in the presence of an antioxidant to a finely divided state.  Preferably, the cartilage is defatted before the grinding step.  The cartilage is preferably obtained from animals not over six months old, the most effective source generally being foetal skeletons.  The proteolytic treatment can be effected with a proteolytic enzyme such as an acid-pepsin solution.  The final product generally has a particle size not exceeding 40 microns. Active woundhealing extracts may be obtained from the cartilage product by treating the latter with aqueous solutions of ammonia, urea or various salts having a pH of 6.5 to 10, preferably in the absence of oxygen or in the presence of an antioxidant.  The aqueous extracts may be concentrated in vacuum or spray-dried or freeze-dried.  The activity of the prepared cartilage is increased by exposing it to irradiation of wavelength not greater than 4000  , e.g. UV light.  A synergistic effect is obtained by admixing the cartilage product with growth hormone or tung oil.  The product may be administered in the form of tablets, capsules, suppositories, ointments, salves (based on aqueous gels, for example, of aluminium hydroxide, kaolin, silica, methylcellulose, alginates, gum tragacanth, gelatin, gluten, casein, polyvinyl pyrrolidone or dextran), solutions, aqueous suspensions, oily suspensions, emulsions, sprays or incorporated with surgical gauze.  Blood, blood plasma or a plasma substitute, e.g. polyvinylpyrrolidone or dextran, may be used as an extending agent.  In one Example (No. 14), pepsin-treated, ground cartilage is held, in powder form, between layers of surgical gauze and held through bandages to an unsutured wound.  In another Example (No. 22), the cartilage is put into the form of enterically coated tablets.